|
Largest Study of Medtronic CoreValve® System Confirms Positive Clinical Outcomes
CoreValve Italian Registry Results Demonstrate Clinical Benefits in a Real-World Patient Population
|
 |
Medtronic's
CoreValve |
|
February 18, 2011 --
Minneapolis -- Medtronic, Inc. (NYSE: MDT) today issued
a statement on results from an independent study published
online in the journal Circulation, which confirmed
both early and sustained clinical benefits for patients receiving
the Medtronic CoreValve® System
for the treatment of aortic valve disease. The article, “Incidence
and Predictors of Early and Late Mortality After Transcatheter
Aortic Valve Implantation in 663 Patients With Severe Aortic
Stenosis,” discusses the largest CoreValve clinical study to
date, with 663 consecutive aortic stenosis patients (mean age
of 81 years) treated at 14 Italian centers beginning immediately
after device commercialization in 2007. |
The article shows that patients receiving CoreValve
have high rates of procedural success (98 percent), low rates of
adverse events (2.1 percent) and substantial improvements of cardiac
function.
The Medtronic CoreValve System is a minimally invasive,
non-surgical treatment option for patients with requiring aortic
valve replacement who are considered at high risk for surgery; CoreValve
is
delivered via transcatheter aortic valve implantation (TAVI) rather
than open-heart surgery. The CoreValve system received CE (Conformité Européenne)
Mark in March 2007 and has been implanted in more than 12,000 patients
worldwide in 42 countries outside the United States. In the U.S.,
the CoreValve System is being evaluated in a U.S. Pivotal Clinical Trial.
Dr.
Corrado Tamburino |
|
"The positive results of our
TAVI experience are encouraging and demonstrate positive clinical
outcomes for a group of patients with few treatment options," said
Corrado Tamburino, M.D., Ph.D., of Ferrarotto Hospital in Catania,
Italy and principal investigator of the study.
"Our findings
demonstrate that a large majority of patients were treated successfully
with CoreValve and experience improvements in heart function.
This real-life registry gives further credence to this new therapy
approach." |
In this
study, procedural success was 98 percent and intraprocedural
mortality was 0.9 percent. Cumulative incidences of mortality
were 5.4 percent at 30 days, 12.2 percent at 6 months,
and 15 percent at one year. Additionally, the study reported low
rates
of permanent pacemaker implantation (16.6 percent at 2-weeks
and 17.4 percent at 30-days).There also was substantial
and sustained improvement in patients’ health status, with 71.5
percent of patients in NYHA class III and IV before the implant
achieving
class I or II after the procedure. The Italian Registry data also evaluated the incidence and predictors of early (30 days) and late (30 days to 1 year) mortality after TAVI. The authors concluded that while early mortality was strongly associated with procedural complications, late mortality was associated with co-morbidities (such as a prior stroke, a prior episode of acute pulmonary edema, or chronic kidney disease) and that pacemaker implant was not a factor.
"We welcome the robust findings from the Italian Registry, which substantially
enhance the strong body of clinical evidence supporting the sustained clinical
benefits of CoreValve in real-life clinical application," said John Liddicoat,
M.D., vice president and general manager of the Structural Heart division at
Medtronic. "We
are committed to supporting clinical evaluation of the CoreValve
system to offer patients with severe aortic stenosis the safest and most adequate
technique for treating this disease." About CoreValve
Approximately 300,000 people worldwide have been diagnosed with this severe aortic stenosis, and approximately one-third of these patients are deemed at too high a risk for open-heart surgery.i The Medtronic CoreValve U.S. Pivotal Clinical Trial began in late 2010 and will enroll more than 1,300 patients at 40 U.S. clinical sites which are identified on www.clinicaltrials.gov. Additional information for patients and referring physicians can be found at www.aorticstenosistrial.com. CoreValve is not yet available in the U.S. for commercial sale or use. About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical
technology – alleviating
pain, restoring health, and extending life for millions of
people around the world. Any forward-looking statements
are subject to risks and uncertainties such as those described
in Medtronic’s periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially
from anticipated results.
i Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Bernard lung et al. Eur Heart J (December 2005) 26(24): 2714-2720.
Source: Medtronic,
Inc.
|
